Martin Bornhäuser

National Center for Tumor Diseases — Germany

Medicine · Health Sciences

95h-index38.7kcitations1.1kworks4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(430), Hematopoietic Stem Cell Transplantation(368), Acute Lymphoblastic Leukemia research(155), Chronic Myeloid Leukemia Treatments(137), Immune Cell Function and Interaction(103)

Publications1.1k total

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype
Annals of Hematology·2026Open Access
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in <scp>AML</scp> Induction Therapy
American Journal of Hematology·2026Open Access
Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction
Journal of Translational Medicine·2025Open Access
Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia
npj Precision Oncology·2025· 1 citedOpen Access
Supplementary Tables S1-S4 from A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
2025Open Access
Supplementary Figures S1-S9 from A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
2025Open Access
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Blood·2025
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia
Bone Marrow Transplantation·2025Open Access
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis
Nature Communications·2025· 1 citedOpen Access
Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes
Blood·2025Open Access
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data
Blood·2025Open Access
Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images
Blood·2025
Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?
Blood·2025
The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML
Blood·2025Open Access
339P LLM-based reasoning framework for MedDRA adverse event coding: Toward scalable automation
ESMO Real World Data and Digital Oncology·2025Open Access
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Leukemia·2025· 3 citedOpen Access
Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia
Cell Death Discovery·2025Open Access
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> Trial
American Journal of Hematology·2025Open Access
Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML
HemaSphere·2025Open Access
PLENARY SESSION 07: TREATMENT LOW RISK MDS (PART 2)
Leukemia Research·2025Open Access
page 1 of 55Next →

Frequent Co-authors

Gerhard Ehninger(27), Christian Thiede(17), Malte von Bonin(13), Johannes Schetelig(11), Christoph Röllig(10), Uwe Platzbecker(9), Rainer Schwerdtfeger(9), Andreas Neubauer(8), Michael Krämer(8), Brigitte Mohr(7), Markus Schaich(7), Matthias Stelljes(7), Jürgen Finke(6), Hermann Einsele(6), Nicolaus Kröger(6), Christoph Schmid(6), Friedrich Stölzel(6), Martin Wermke(5), Wolfgang Bethge(5), Ernst Holler(5)